Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer: Symptoms, Risc Factors, and Prevention
N/A
N/A
Male
Prostate Cancer, Androgen Deprivation Therapy, Osteoporosis
Trial Information
Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer: Symptoms, Risc Factors, and Prevention
Patients with advanced prostate cancer are included at the initiating of androgen
deprivation therapy.
The patients are followed for 2 years after inclusion with blood sampling, DXA-scan,
questionnaire, bone scintigraphy.
Inclusion Criteria:
- Prostate cancer
- Initiation of androgen deprivation therapy
- Oral and written informed consent
Exclusion Criteria:
- They withdraw their consent
- Treatment for osteoporosis within the last year
- Other malignancy
- Other bone disease, bedbound, use of steroid
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
Osteoporosis, either T-score < -2,5 or osteoporosis fracture
Outcome Time Frame:
2½ years
Safety Issue:
No
Principal Investigator
Mads H Poulsen, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Department of Urology, Odense University Hospital, Denmark
Authority:
Denmark: National Board of Health
Study ID:
PCa & Osteoporosis 09
NCT ID:
NCT00957606
Start Date:
August 2009
Completion Date:
September 2013
Related Keywords:
- Prostate Cancer
- Androgen Deprivation Therapy
- Osteoporosis
- Prostate cancer
- androgen deprivation therapy
- osteoporosis
- Osteoporosis
- Prostatic Neoplasms
Name | Location |
|---|
